ClinicalTrials.gg
CompletedNCT06224595Updated Dec 3, 2024

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules

A Phase 1 interventional study of CS32582 capsule and Placebo capsule in Healthy, sponsored by Chipscreen Biosciences, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CS32582 after single or multiple oral administration, as well as the food effect on the pharmacokinetics in healthy subjects.

Read the detailed description

This study consists of 3 parts: single ascending dose (SAD), food effect (FE) and multiple ascending dose (MAD). Both SAD and MAD study are randomized, double-blind, placebo-controlled design. The FE study is a randomized, open-label, two-period, two-crossover design.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Chipscreen Biosciences, Ltd. is the lead sponsor of 42 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects, both male and female.
  • Between18 and 55 years of age (inclusive) at screening visit.
  • between 19.0-26.0 kg/m\^2 (including critical value) at screening visit and baseline visit, male subjects' body weight ≥ 50 kg, female subjects' body weight ≥45 kg.
  • Subject is medically healthy or judged by the investigator to be abnormal but clinically insignificant based on the results of history inquiry, physical examination, vital signs, standard 12-lead , X-ray, abdominal ultrasound examination, and clinical laboratory tests at the time of screening visit.
  • All subjects and female partners of male agree to use medically recognized effective methods of (including physical contraception, surgical contraception, abstinence, etc.) from the start of signing form to 3 months after the last dose.
  • Subjects voluntarily participate in the study and sign informed consent form.

Exclusion criteria

Exclusion Criteria:

  • History of drug allergy or atopic allergic diseases (asthma, urticaria, eczematous dermatitis) or drug allergy to products or similar investigational products.
  • History of cardiovascular system, endocrine system, nervous system, respiratory system, digestive system, liver, kidney, blood and lymphatic system, immune system, psychiatric diseases and metabolic abnormalities.
  • Conditions that may affect the determination of skin adverse events related to the investigational drug, including but not limited to sunburn, excessive tattooing (covering more than 25% of body surface area), or existing acne extending beyond sebum-prone areas (i.e., arms, torso, back, buttocks, and/or genital area).
  • History of myalgia or rhabdomyolysis.
  • History of hereditary hyperbilirubinemia.
  • History of gastrointestinal, hepatic, or renal diseases or surgeries within the past 6 months that could affect drug absorption or metabolism, excluding uncomplicated appendectomy and hernia repair.
  • History of active tuberculosis or positive tuberculosis at the screening visit.
  • History of recurrent bacterial, fungal, or viral infections (≥3 occurrences in the past year, excluding common cold), or active infection requiring treatment at the screening visit, or history of infection within ≤8 weeks before baseline visit requiring intravenous anti-infective drugs and/or hospitalization, or history of infection requiring oral anti-infective drugs ≤2 weeks before baseline visit.
  • Untreated diarrhea at baseline visit or diarrhea symptoms within 7 days before the planned first dose.
  • History of drug abuse.
  • Vaccination within the past 3 months at the screening visit or plans for any vaccination during the study.
  • Participation in an interventional clinical trial (device or drug) within the past 3 months or use of investigational drugs within the past 3 months or still within 5 half-life of that drug (whichever is longer) at the screening visit.
  • Blood donation or significant blood loss (>300 mL) within the past 3 months at the screening visit.
  • Use of any prescription drugs, non-prescription drugs, any vitamin products, or herbal products within the past month before baseline visit.
  • Inability to tolerate venepuncture or history of needle or blood-related fainting.
  • Regular alcohol consumption exceeding 7 drinks per week for females or 14 drinks per week for males in the past 3 months at the screening visit, or use of any alcohol-containing product within 48 hours before the planned first dose.
  • Smoking more than 5 cigarettes or equivalent tobacco daily within the past 3 months at the screening visit or inability to quit smoking during the study.
  • Consumption of excessive tea, coffee, and/or caffeine-containing beverages (more than 8 cups) daily within the past 14 days before baseline visit, or consumption of tea, coffee, and/or caffeine-containing beverages or foods within 48 hours before the planned first dose.
  • Consumption of grapefruit or grapefruit-containing products within the past 14 days before baseline visit.
  • Systolic blood pressure less than 90 mmHg or greater than 140 mmHg, and/or diastolic blood pressure less than 60 mmHg or greater than 90 mmHg at screening and baseline visits.
  • (eGFR) \<90 mL/min (calculated using CKD-EPI equation with blood creatinine, age, and gender) at screening and baseline visits.
  • ≥450 ms or other clinically significant abnormalities of standard 12-lead judged by the investigator at screening and baseline visits.
  • Meeting any of the following at screening and baseline visits: Blood routine: White blood cell count \<3.5×10\^9/L or \<1.8×10\^9/L or \<115 g/L for females or \<130 g/L for males; or count \<125×10\^9/L. Blood creatinine above the (ULN). or aspartate aminotransferase or total or direct bilirubin above ULN.
  • Inability to provide a negative (HIV) antibody report at screening visit.
  • Positive results for syphilis serology, surface antigen (HBsAg), HBV-DNA quantification, or virus antibody (HCV-Ab) at screening and baseline visits.
  • Positive urine drug abuse screening (opiates, methamphetamine, ketamine, ecstasy, marijuana, cocaine) or positive alcohol breath test at screening and baseline visits.
  • Pregnant or lactating females, or females with serum human chorionic gonadotropin (HCG) ≥5 mIU/mL.
  • Need or plan to engage in strenuous physical activity or exercise during the study.
  • Participants unable to tolerate a high-fat meal (applicable only to participants in postprandial trials).
  • Participants with swallowing difficulties.
  • Other situations deemed unsuitable for participation in the clinical trial by the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    CS32582 Cohort 1

    Subjects receive a single dose of 3 mg CS32582 or matching placebo

    Drug: CS32582 capsule · Drug: Placebo capsule

  • Experimental
    CS32582 Cohort 2

    Subjects receive a single dose of 6 mg CS32582 or matching placebo

    Drug: CS32582 capsule · Drug: Placebo capsule

  • Experimental
    CS32582 Cohort 3

    Subjects receive a single dose of 12 mg CS32582 or matching placebo

    Drug: CS32582 capsule · Drug: Placebo capsule

  • Experimental
    CS32582 Cohort 4

    Subjects receive a single dose of 24 mg CS32582 or matching placebo

    Drug: CS32582 capsule · Drug: Placebo capsule

  • Experimental
    CS32582 Cohort 5

    Subjects receive a single dose of 36 mg CS32582 or matching placebo

    Drug: CS32582 capsule · Drug: Placebo capsule

  • Experimental
    CS32582 Cohort 6

    Subjects receive a single dose of 54 mg CS32582 or matching placebo

    Drug: CS32582 capsule · Drug: Placebo capsule

  • Experimental
    CS32582 Cohort 7

    Subjects receive a single dose 12 mg CS32582 in either the fasted or fed state for two periods

    Drug: CS32582 capsule

  • Experimental
    CS32582 Cohort 8

    Subjects receive 3 mg CS32582 or matching placebo for 10 days, twice daily (every 12 h) from Day 1 to Day 9, and once on Day 10.

    Drug: CS32582 capsule · Drug: Placebo capsule

  • Experimental
    CS32582 Cohort 9

    Subjects receive 6 mg CS32582 or matching placebo for 10 days, twice daily (every 12 h) from Day 1 to Day 9, and once on Day 10.

    Drug: CS32582 capsule · Drug: Placebo capsule

  • Experimental
    CS32582 Cohort 10

    Subjects receive 12 mg CS32582 or matching placebo for 10 days, once daily from Day 1 to Day 10.

    Drug: CS32582 capsule · Drug: Placebo capsule

  • Experimental
    CS32582 Cohort 11

    Subjects receive 12 mg CS32582 or matching placebo for 10 days, twice daily (every 12 h) from Day 1 to Day 9, and once on Day 10.

    Drug: CS32582 capsule · Drug: Placebo capsule

Interventions

  • DrugCS32582 capsule

    Participants receive CS32582 orally single or multiple doses

  • DrugPlacebo capsule

    Participants receive placebo matching CS32582 orally single or multiple doses

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events (AEs)

    To investigate the safety and tolerability by assessment of AEs following administration.

    Time frame: From the time of signing the informed consent form to 7 days after the last administration of the drug

  2. Pharmacokinetic parameters - Area Under the Curve(AUC)

    Area Under the Plasma Concentration-time Curve of CS32582.

    Time frame: From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses. From time 0 to 48 hours after each period's dosing for food effect study.

  3. Pharmacokinetic parameters - Peak Plasma Concentration (Cmax)

    Maximum Observed Plasma Concentration of CS32582.

    Time frame: From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses. From time 0 to 48 hours after each period's dosing for food effect study.

  4. Pharmacokinetic parameters - Time of Peak Concentration(Tmax)

    Time to reach maximum observed plasma concentration of CS32582.

    Time frame: From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses. From time 0 to 48 hours after each period's dosing for food effect study.

  5. Pharmacokinetic parameters - Plasma Elimination Half-Life(t1/2)

    Plasma Elimination Half-Life of CS32582.

    Time frame: From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses. From time 0 to 48 hours after each period's dosing for food effect study.

07

Study locations

1 site
  • Zhongshan Hospital Affiliated to Fudan University
    Shanghai, Shanghai 200032, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Nov 2024, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Jan 25, 2024
StartActual
Mar 28, 2024
Primary completionActual
Nov 27, 2024
CompletionActual
Nov 27, 2024
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06224595
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Mar 28, 2024
Primary completion
Nov 27, 2024
Completion
Nov 27, 2024
Last update
Dec 3, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion